Literatura académica sobre el tema "Variants du SARS-CoV-2"
Crea una cita precisa en los estilos APA, MLA, Chicago, Harvard y otros
Consulte las listas temáticas de artículos, libros, tesis, actas de conferencias y otras fuentes académicas sobre el tema "Variants du SARS-CoV-2".
Junto a cada fuente en la lista de referencias hay un botón "Agregar a la bibliografía". Pulsa este botón, y generaremos automáticamente la referencia bibliográfica para la obra elegida en el estilo de cita que necesites: APA, MLA, Harvard, Vancouver, Chicago, etc.
También puede descargar el texto completo de la publicación académica en formato pdf y leer en línea su resumen siempre que esté disponible en los metadatos.
Artículos de revistas sobre el tema "Variants du SARS-CoV-2"
Huamán Saavedra, Juan Jorge. "SARS-COV-2 variants". Revista Médica de Trujillo 16, n.º 1 (16 de marzo de 2021): 1–2. http://dx.doi.org/10.17268/rmt.2020.v16i01.01.
Texto completoScarpa, Fabio, Francesco Branda, Nicola Petrosillo y Massimo Ciccozzi. "On the SARS-CoV-2 Variants". Infectious Disease Reports 16, n.º 2 (26 de marzo de 2024): 289–97. http://dx.doi.org/10.3390/idr16020024.
Texto completoLiang, Hong-Yu, Yuyan Wu, Vicky Yau, Huan-Xin Yin, Scott Lowe, Rachel Bentley, Mubashir Ayaz Ahmed, Wenjing Zhao y Chenyu Sun. "SARS-CoV-2 Variants, Current Vaccines and Therapeutic Implications for COVID-19". Vaccines 10, n.º 9 (16 de septiembre de 2022): 1538. http://dx.doi.org/10.3390/vaccines10091538.
Texto completoHassan, Dlshad Abdullah, Sazan Qadir Maulud, Rzgar Farooq Rashid, Jivan Qasim Ahmed y Rezhna Khider Ali. "Molecular Epidemiology of SARS-CoV-2 Variants in Vaccinated and Non-Vaccinated Patients of Erbil Province, Kurdistan Region-Iraq". BioMed Target Journal 2, n.º 1 (3 de mayo de 2024): 24–29. http://dx.doi.org/10.59786/bmtj.213.
Texto completoCaputo, Emilia y Luigi Mandrich. "SARS-CoV-2: Searching for the Missing Variants". Viruses 14, n.º 11 (26 de octubre de 2022): 2364. http://dx.doi.org/10.3390/v14112364.
Texto completoLauring, Adam S. y Preeti N. Malani. "Variants of SARS-CoV-2". JAMA 326, n.º 9 (7 de septiembre de 2021): 880. http://dx.doi.org/10.1001/jama.2021.14181.
Texto completoTang, Ziyang. "A Study on the Relationship between the 3-D Structure of Spike Proteins and Infectiousness of SARS-CoV-2 Delta Variant". Highlights in Science, Engineering and Technology 8 (17 de agosto de 2022): 169–77. http://dx.doi.org/10.54097/hset.v8i.1124.
Texto completoLu, Yonghua, Tianfu Zhao, Ming Lu, Yaopeng Zhang, Xiang Yao, Guoyi Wu, Fangyin Dai, Fengxiu Zhang y Guangxian Zhang. "The Analyses of High Infectivity Mechanism of SARS-CoV-2 and Its Variants". COVID 1, n.º 4 (24 de noviembre de 2021): 666–73. http://dx.doi.org/10.3390/covid1040054.
Texto completoMishra, Mitali, Aleena Zahra, Lokendra V. Chauhan, Riddhi Thakkar, James Ng, Shreyas Joshi, Eric D. Spitzer, Luis A. Marcos, W. Ian Lipkin y Nischay Mishra. "A Short Series of Case Reports of COVID-19 in Immunocompromised Patients". Viruses 14, n.º 5 (29 de abril de 2022): 934. http://dx.doi.org/10.3390/v14050934.
Texto completoDe Pace, Vanessa, Bianca Bruzzone, Andrea Orsi, Valentina Ricucci, Alexander Domnich, Giulia Guarona, Nadia Randazzo et al. "Comparative Analysis of Five Multiplex RT-PCR Assays in the Screening of SARS-CoV-2 Variants". Microorganisms 10, n.º 2 (27 de enero de 2022): 306. http://dx.doi.org/10.3390/microorganisms10020306.
Texto completoTesis sobre el tema "Variants du SARS-CoV-2"
CIMINO, Anna Rita. "Amphiphilic and ganglioside-binding properties of SARS CoV-2 Spike protein variants dissected by charge shift electrophoresis in deterged solution". Doctoral thesis, Università degli studi del Molise, 2022. https://hdl.handle.net/11695/115828.
Texto completoSaade, Carla. "Immune response against SARS-CoV-2 : impact of viral variants, vaccination, and protection against reinfection". Electronic Thesis or Diss., Lyon 1, 2024. http://www.theses.fr/2024LYO10271.
Texto completoThe COVID-19 pandemic has presented significant challenges to global healthcare, largely due SARS-CoV-2’s ability to acquire new mutations. This has led to the sequential emergence of variants of concern (VOCs) such as Alpha, Beta, Delta, and now Omicron that exhibited different successive subvariants (notably BA.1, JN.1, and KP.3). These VOCs have raised concerns about their capacity to escape the immune response induced by infection and/or vaccination. As vaccination campaigns continue worldwide, it is crucial to evaluate how different immunization schemes, including homologous and heterologous vaccinations as well as infection combined with vaccination (hybrid immunity), impact the immune response against emerging variants. With a prospective cohort of healthcare workers, this PhD project aimed to investigate i) the capacity of viral variants to escape the immune response, ii) the effectiveness of different immunization schemes, and iii) the durability of the resulting immune responses. Our findings indicated that the Alpha and Beta variants are able to escape neutralizing antibodies induced by immunization against the ancestral strain, regardless of the immunization scheme. This capacity for immune evasion extends beyond these earlier variants, as both the Delta and Omicron variants also demonstrated significant resistance to neutralization by antibodies elicited through prior immunization. Such findings underscore the critical need to consider variant-specific immune escape when establishing protection thresholds and updating vaccination strategies. In addition to viral immune escape the waning of the immune response also contributes to a decreased protection against SARS-CoV-2. Our results show that the type of immunization, i.e. infection or vaccination, significantly influences the peak levels and half-life of antibodies targeting the receptor binding domain (RBD). This led us to investigate the immune response induced by different immunization schemes 6 months post-immunization. In particular, we showed that hybrid immunity leads to a more robust immune response 6 months post-immunization compared to immunity induced by either infection or vaccination alone. This enhanced response is observed across various immunological parameters, such as neutralization capacity and the pool of memory B cells, and translates into significantly improved protection against the Delta variant. Individuals with hybrid immunity experienced a 4.5-fold reduction in the risk of Delta infection compared to those with immunity induced solely by homologous vaccination. These findings highlight the importance of considering these differences when formulating vaccination recommendations. Nevertheless, breakthrough infections, i.e. infections occurring despite previous vaccination, are frequently reported during the Omicron era among individuals fully-vaccinated and those with hybrid immunity. Our investigation into the humoral immune response following BA.1 breakthrough infection revealed that while hybrid immunity prevents an increase in anti-S IgG4 levels and maintains a high antibody-dependent cellular cytotoxicity (ADCC) activity, it limits the diversification of the RBD-specific memory B cell pool compared to vaccination-induced immunity. Hence, our results indicate that BA.1 breakthrough infection elicits distinct immune responses that vary based on prior immunization schemes, which emphasizes the interest to consider immunization history with the aim to personalize vaccination recommendations. Overall, the results obtained throughout this PhD project emphasize the need to incorporate prior immunization history into ongoing adjustments of vaccination strategies and policies to effectively address the evolving immune escape capabilities of VOCs
Galmiche, Simon. "Identifying the settings at risk of transmission of SARS-CoV-2, the role of children in household transmission, and the incubation period of the main variants in an online case-control study in France". Electronic Thesis or Diss., Sorbonne université, 2024. https://accesdistant.sorbonne-universite.fr/login?url=https://theses-intra.sorbonne-universite.fr/2024SORUS144.pdf.
Texto completoWe aimed to identify the community settings associated with the risk of SARS-CoV-2 infection, the role of children in household transmission, and the incubation period of the SARS-CoV-2 infection. In a case-control study conducted in mainland France among adults with recent infection and uninfected controls matched on age, sex, region, population size, and calendar week, we estimated the odds ratios of SARS-CoV-2 infection for community settings, behaviours, activities, and children presence in the household. We leveraged the case series to describe the circumstances of transmission. We studied the effect of intra-household isolation from a child with ongoing infection. We determined the incubation period across variants of SARS-CoV-2. Between October 2020 and October 2022, we included 691,454 cases and 57,065 controls. After matching 175,688 cases with 43,922 controls (4:1) across the study divided into nine periods, we identified the risk associated with shared offices, shared transport, and leisure activities. Among the cases who could identify the source of transmission, the most reported transmissions took place in the household, with extended family or friends, or in the workplace. People living with children were at increased risk of infection, but isolation from an infected child (particularly ventilation of indoor areas) was associated with decreased transmission. The incubation period of the omicron variant was shorter by approximately 1 day compared with the historical strain. The evidence provided by this study on the transmission of SARS-CoV-2 will help design mitigation strategies in the context of pandemic preparedness
Unelind, Malin. "Det vi vet om ursprunget och evolutionen av SARS-CoV-2 : - Implementering av aktuella händelser i gymnasieskolan". Thesis, Linköpings universitet, Institutionen för fysik, kemi och biologi, 2021. http://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-178796.
Texto completoThe outbreak of SARS-CoV-2 occurred at the end of 2019 and three months later, it was declared as a pandemic. Today, roughly one and a half years later, people across the world are still struggling to get out of the crises caused by the pandemic. Despite the huge efforts within science, much is still uncertain about the virus’ origin. Different theories are trying to be proven by scientists but to date, there is no confirmation from where the virus has its origin, nor whether one or several intermediate hosts have been involved. It seems likely that SARS- CoV-2 has a common ancestor with the bat β-coronavirus RaTG13. Therefore, it is probable that bats with at least one other intermediate host have been involved in the origin of the virus. Several variants have emerged and spread throughout the world. Global cooperation in regards of surveilling mutations and variants is of great importance regarding the development of the pandemic. Using SARS-CoV-2 and the Covid-19 pandemic as a focal point, there is an analysis showing opportunities and challenges when teaching big contemporary events.
Eriksson, Johanna. "Förekomst av SARS-CoV-2 varianter av särskild betydelse i Region Dalarna, december 2020-januari 2021". Thesis, Örebro universitet, Institutionen för hälsovetenskaper, 2021. http://urn.kb.se/resolve?urn=urn:nbn:se:oru:diva-92995.
Texto completoBackground: The ongoing pandemic COVID-19 is caused by the virus SARS-CoV-2. Since December 2020 new variants of the virus with significant mutations have been discovered, referred to as variants of concern (VOC). At the point, the occurrence of three VOC is especially monitored; B.1.1.7 (discovered in UK), B.1.351 (discovered in South Africa) and P.1 (discovered in Brazil). The earliest statistics about the occurrence of VOC in Region Dalarna, Sweden, is from February 2021 and the occurrence before that is still unknown. In the region analysis of specimen in case of suspected COVID-19 is divided into the different categories patients, healthcare-staff, infection tracing and public. Existing statistics is based almost exclusively on the occurrence of VOC in specimen from the public. Aim: The aim of this study was to examine the occurrence of SARS-CoV-2 VOC among specimens collected from patients, healthcare staff and infection tracing in Region Dalarna during December 2020-January 2021. The study also aimed to examine when the spread of each VOC started in the region. Method: SARS-CoV-2 positive specimen collected within the categories during the time was analyzed with RT-PCR and melting curve analysis for detection of VOC-characteristic mutations. Results: A few cases of B.1.1.7 was detected already in December and an increased percentage of B.1.1.7 was detected within the categories during January, suggesting that a regional spread started at the time. Only a few cases of B.1.351 and/or P.1 was detected within the categories, suggesting that a regional spread of these had not yet started in January.
Libros sobre el tema "Variants du SARS-CoV-2"
Chavda, Vivek P. y Vladimir N. Uversky. SARS-CoV-2 Variants and Global Population Vulnerability. New York: Apple Academic Press, 2024. http://dx.doi.org/10.1201/9781003467939.
Texto completoSARS-CoV-2 Variants - Two Years After [Working Title]. IntechOpen, 2022. http://dx.doi.org/10.5772/intechopen.100818.
Texto completoEl-Shamy, Ahmed y Mohamed Ibrahim, eds. What SARS-CoV-2 Variants Have Taught Us: Evolutionary Challenges of RNA Viruses. MDPI, 2024. http://dx.doi.org/10.3390/books978-3-0365-9832-1.
Texto completoSARS-CoV-2 Variants and Global Population Vulnerability: Diagnostic Strategies, Vaccine Development, and Therapeutic Management. Apple Academic Press, Incorporated, 2024.
Buscar texto completoSARS-CoV-2 Variants and Global Population Vulnerability: Diagnostic Strategies, Vaccine Development, and Therapeutic Management. Apple Academic Press, Incorporated, 2024.
Buscar texto completoFocosi, Daniele. SARS-CoV-2 Spike Protein Convergent Evolution: Impact of Virus Variants on Efficacy of COVID-19 Therapeutics and Vaccines. Springer International Publishing AG, 2021.
Buscar texto completoUmar. SARS-CoV-2 Omicron Variant: A Complete Guide for New Virus Omicron Variant. Independently Published, 2022.
Buscar texto completoAYRTON MATHEUS DA SILVA, NASCIMENTO, SILVA ERICK VIANA DA y VIANA KILMA DA SILVA LIMA. TRANSFORMAÇÃO E EVOLUÇÃO EM TEMPOS DISRUPTIVOS. INSTITUTO INTERNACIONAL DESPERTANDO VOCAÇÕES, 2022. http://dx.doi.org/10.31692/978-65-88970-23-2.
Texto completoCapítulos de libros sobre el tema "Variants du SARS-CoV-2"
Focosi, Daniele. "SARS-CoV-2 Variants". En SpringerBriefs in Microbiology, 55–71. Cham: Springer International Publishing, 2021. http://dx.doi.org/10.1007/978-3-030-87324-0_6.
Texto completoGoswami, Srijan, Ushmita Gupta Bakshi y Shreya Bhattacharya. "SARS-CoV-2 and Its Variants". En COVID-19 and SARS-CoV-2, 49–60. Boca Raton: CRC Press, 2022. http://dx.doi.org/10.1201/9781003178514-5.
Texto completoFocosi, Daniele. "Characterization of SARS-CoV-2 Variants". En SpringerBriefs in Microbiology, 73–74. Cham: Springer International Publishing, 2021. http://dx.doi.org/10.1007/978-3-030-87324-0_7.
Texto completoGhione, Giorgia, Marta Lovino, Elisa Ficarra y Giansalvo Cirrincione. "BERT Classifies SARS-CoV-2 Variants". En Applications of Artificial Intelligence and Neural Systems to Data Science, 157–63. Singapore: Springer Nature Singapore, 2023. http://dx.doi.org/10.1007/978-981-99-3592-5_15.
Texto completoRubio-Casillas, Alberto y Vladimir N. Uversky. "SARS-CoV-2 Life Cycle and Immuno-Pathophysiology". En SARS-CoV-2 Variants and Global Population Vulnerability, 19–65. New York: Apple Academic Press, 2024. http://dx.doi.org/10.1201/9781003467939-2.
Texto completoPeacock, Sharon J. "SARS-CoV-2 Variants: Past, Present and Future". En Economics, Law, and Institutions in Asia Pacific, 3–23. Singapore: Springer Singapore, 2021. http://dx.doi.org/10.1007/978-981-16-5727-6_1.
Texto completoMalhotra, Hitesh, Amrit Sarwara, Vandana Garg, Rohit Dutt, Vineet Mittal y Rajeev K. Singla. "Herbal Remedies for COVID-19 Management". En SARS-CoV-2 Variants and Global Population Vulnerability, 391–412. New York: Apple Academic Press, 2024. http://dx.doi.org/10.1201/9781003467939-13.
Texto completoLundstrom, Kenneth. "Role of Nucleic Acid Vaccines for the Management of Emerging Variants of SARS-CoV-2". En SARS-CoV-2 Variants and Global Population Vulnerability, 285–316. New York: Apple Academic Press, 2024. http://dx.doi.org/10.1201/9781003467939-10.
Texto completoJoshi, Mit y Bhoomika M. Patel. "COVID-19 and Post-COVID-19-Associated Complications and Their Management". En SARS-CoV-2 Variants and Global Population Vulnerability, 413–42. New York: Apple Academic Press, 2024. http://dx.doi.org/10.1201/9781003467939-14.
Texto completoSingh, Ashutosh, Rehan Fazal, Upasana Sahu, Manoj Kumar, Sandeep Bhatia, Aniket Sanyal y Naveen Kumar. "Zoonotic Origin, Genomic Organization, Transmission, and Mutation of SARS-CoV-2". En SARS-CoV-2 Variants and Global Population Vulnerability, 1–18. New York: Apple Academic Press, 2024. http://dx.doi.org/10.1201/9781003467939-1.
Texto completoActas de conferencias sobre el tema "Variants du SARS-CoV-2"
Silva, LP, LFR Velasco, FA Hurtado, ASC Oliveira, GL Souza, MS Andrade, A. Belmok y CF Sousa. "GENOTIPAGEM DO SARS-COV-2 EM AMOSTRAS DO DISTRITO FEDERAL". En Resumos do 54º Congresso Brasileiro de Patologia Clínica/Medicina Laboratorial, 25. Zeppelini Editorial e Comunicação, 2022. http://dx.doi.org/10.5327/1516-3180.140s1.5829.
Texto completo"Emergence of SARS-CoV-2 Variant of Concern Omicron: Biological Features and Genomic Concern". En International Conference on Public Health and Humanitarian Action. International Federation of Medical Students' Associations - Jordan, 2022. http://dx.doi.org/10.56950/itrx2370.
Texto completoAjayi, Oluwaseyi y Tarek Saadawi. "Enhancing SARS-CoV-2 variants Research with Blockchain Architecture". En 2022 IEEE International IOT, Electronics and Mechatronics Conference (IEMTRONICS). IEEE, 2022. http://dx.doi.org/10.1109/iemtronics55184.2022.9795830.
Texto completoSmatti, Maria K., Yasser Al-Sarraj, Omar Albagha y Hadi M. Yassine. "Host Genetic Variants Potentially Associated with SARS-Cov-2: A Multi-Population Analysis". En Qatar University Annual Research Forum & Exhibition. Qatar University Press, 2020. http://dx.doi.org/10.29117/quarfe.2020.0298.
Texto completoSolodkov, P. P., T. N. Belovezhets, A. N. Chikaev, K. O. Baranov, S. V. Kulemzin, A. A. Gorchakov, S. V. Guselnikov et al. "SINGLE DOMAIN LLAMA ANTIBODIES BROADLY NEUTRALIZING SARS-COV-2 VARIANTS". En X Международная конференция молодых ученых: биоинформатиков, биотехнологов, биофизиков, вирусологов и молекулярных биологов — 2023. Novosibirsk State University, 2023. http://dx.doi.org/10.25205/978-5-4437-1526-1-127.
Texto completoDias, Brenda, Andrea Silva, Ariane Souza, Luma Moura, Nathália Alves, Vanessa Rocha, Ana Argondizzo, Sheila Lima, Helena Toma y Adriana Azevedo. "Neutralizing antibodies and igg avidity against SARS-CoV-2 variants". En International Symposium on Immunobiologicals. Instituto de Tecnologia em Imunobiológicos, 2023. http://dx.doi.org/10.35259/isi.2023_58035.
Texto completoZainutdinov, S. S., G. A. Kudrov, A. V. Shipovalov, Yu A. Merkuleva y I. S. Shulgina. "VECTOR SYSTEM BASED ON THE SENDAI VIRUS FOR THE DEVELOPMENT OF INTRANASAL VACCINES AGAINST RESPIRATORY INFECTIONS USING THE EXAMPLE OF COVID-19". En OpenBio-2023. Novosibirsk State University, 2023. http://dx.doi.org/10.25205/978-5-4437-1526-1-248.
Texto completoBenslimane, Fatiha M., Hebah Al Khatib, Dana Albatesh, Ola Al-Jamal, Sonia Boughattas, Asmaa A. Althani y Hadi M. Yassine. "Nanopore Sequencing SARS-CoV-2 Genome in Qatar". En Qatar University Annual Research Forum & Exhibition. Qatar University Press, 2020. http://dx.doi.org/10.29117/quarfe.2020.0289.
Texto completoLopez, Edgar Clyde R. "Structure-Based Screening of Potential Drugs against SARS-CoV-2 Variants". En The 4th International Electronic Conference on Applied Sciences. Basel Switzerland: MDPI, 2023. http://dx.doi.org/10.3390/asec2023-15536.
Texto completoBhattacharya, Debarpan, Debottam Dutta, Neeraj Sharma, Srikanth Raj Chetupalli, Pravin Mote, Sriram Ganapathy, Chandrakiran C et al. "Analyzing the impact of SARS-CoV-2 variants on respiratory sound signals". En Interspeech 2022. ISCA: ISCA, 2022. http://dx.doi.org/10.21437/interspeech.2022-10389.
Texto completoInformes sobre el tema "Variants du SARS-CoV-2"
Vagnoni, Cristiana. Which SARS-CoV-2 variants reduce the effectiveness of vaccines? Parliamentary Office of Science and Technology, abril de 2021. http://dx.doi.org/10.58248/rr65.
Texto completoBorder, Peter. SARS-CoV-2 virus variants: a year into the COVID-19 pandemic. Parliamentary Office of Science and Technology, enero de 2021. http://dx.doi.org/10.58248/rr58.
Texto completoTuite, Ashleigh R., David N. Fisman, Ayodele Odutayo, Pavlos Bobos, Vanessa Allen, Isaac I. Bogoch, Adalsteinn D. Brown et al. COVID-19 Hospitalizations, ICU Admissions and Deaths Associated with the New Variants of Concern. Ontario COVID-19 Science Advisory Table, marzo de 2021. http://dx.doi.org/10.47326/ocsat.2021.02.18.1.0.
Texto completoBunn, Sarah. COVID-19: Omicron, recent developments, and the likely impact of future variants on the pandemic. Parliamentary Office of Science and Technology, marzo de 2022. http://dx.doi.org/10.58248/rr78.
Texto completoDesveaux, Laura, Rhiannon Mosher, Judy L. Buchan, Rachel Burns, Kimberly M. Corace, Gerald A. Evans, Leandre R. Fabrigar et al. Behavioural Science Principles for Enhancing Adherence to Public Health Measures. Ontario COVID-19 Science Advisory Table, abril de 2021. http://dx.doi.org/10.47326/ocsat.2021.02.24.1.0.
Texto completoBetancur Ortiz, Idabely, Cristian Arbey Velarde y Celeny Ortiz Restrepo. Situación epidemiológica de las variantes del virus SARS-CoV-2 detectadas en Antioquia, de diciembre 2020 a enero 2022. Instituto Nacional de Salud, enero de 2022. http://dx.doi.org/10.33610/01229907.2022v4n1a4.
Texto completoBunn, Sarah. COVID-19: The Omicron Variant. Parliamentary Office of Science and Technology, diciembre de 2021. http://dx.doi.org/10.58248/rr75.
Texto completoMoreno, Viviana Carolina, Ximena Castro, Claudia Marcela Muñoz y Giomar Sichaca Ávila. Situación de salud pública y migración en tiempos de pandemia, Necoclí, Antioquia, 2021. Instituto Nacional de Salud, enero de 2022. http://dx.doi.org/10.33610/01229907.2022v4n1a1.
Texto completoPlans for SARS-CoV-2 variant assessment and response. Public Health Scotland, septiembre de 2022. http://dx.doi.org/10.52487/96298.
Texto completo